Celgene must be doing something right.
On Monday, shares of biotech firm Celgene (nasdaq: CELG - news - people ) ticked up 2.9%, or $1.44, to $51.09, in morning trading after it announced late-Sunday that it expects its 2007 earnings to double on the spiking sales of its blood cancer drug Revlimid.
Link to Article
Forbes.com
|
|
||||||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Celgene Rides High On Cancer Drug
by
Alex Hsieh on behalf of Professor Henry Wang
on Mon 07 Jan 2008 11:21 PM EST | Permanent Link
| Cosmos
No comments found.
|
Search
Links
|
||||||